Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.62 |
| ▸ | CDK1 | P06493 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466766 | 0.88 | CDK2 (0.62) | CDK2CDK1CA2CA12CA9 | |
| SCHEMBL4475239 | 0.87 | CDK2 (0.62) | CDK2CDK1CA2CA12CA9 | |
| SCHEMBL13931766 | 0.87 | CDK2 (0.48) | CDK2CDK1CA2CA12CA9 | |
| SCHEMBL5510994 | 0.87 | CA12 (0.50) | CDK2CDK1CA2CA12CA9 | |
| SCHEMBL13918111 | 0.87 | IKBKB (0.54) | CDK2CDK1CA2CA12CA9 | |
| SCHEMBL4466637 | 0.86 | CDK2 (0.65) | CDK2CDK1CA2CA12CA9 | |
| SCHEMBL13931858 | 0.85 | CDK2 (0.46) | CDK2CDK1CA2CA12CA9 | |
| SCHEMBL4460780 | 0.84 | CDK2 (0.65) | CDK2CDK1CA2CA12CA9 | |
| Gw831091X SCHEMBL4464647 | 0.83 | CDK2 (0.65) | CDK2CDK1CA2CA12CA9 | |
| SCHEMBL4467252 | 0.80 | CDK2 (0.64) | CDK2CDK1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | claimed |
| EP-1597234-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1597234-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-11-21 | — | — | EP | claimed |
| US-20060142284-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2006-06-29 | — | — | US | claimed |
| EP-1597234-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004076414-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-10 | — | — | WO | claimed |
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1597234-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1597234-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20060142284-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142284-A1 | Novel compounds | CDK2, CDK3, CDK2AP2 | CDK2 1/4885CDK1 6/4885CA2 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.